Efficacy of a short course of intensive therapy with TGF-β2-enriched enteral nutrition for severe gastrointestinal toxicity: a case report
Olga A. Obukhova , Ildar A. Kurmukov , Grigory S. Yunaev
Clinical nutrition and metabolism ›› 2024, Vol. 5 ›› Issue (2) : 86 -92.
Efficacy of a short course of intensive therapy with TGF-β2-enriched enteral nutrition for severe gastrointestinal toxicity: a case report
Background: Timely and successful treatment of chemotherapy-induced gastrointestinal toxicity ensures continued antitumor therapy in patients with cancer. Severe diarrhea can lead to dehydration and refusal of further cytostatic treatment. We present a clinical case of severe gastrointestinal toxicity requiring complex intensive therapy.
Case description: A 63-year-old male diagnosed with stage IV infiltrative ascending colon cancer with multiple liver metastases, T3N1M1, underwent four cycles of antitumor therapy following the FOLFOXIRI regimen (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) combined with bevacizumab, which was later discontinued due to thrombotic events. After the fifth cycle of FOLFOXIRI chemotherapy, grade 3 diarrhea developed, leading to dehydration and requiring complex intensive therapy, including TGF-β2-enriched enteral nutrition. The intervention was successful, enabling timely continuation of chemotherapy.
Conclusion: Considering the pathophysiology of drug-induced diarrhea, additional outpatient TGF-β2-enriched enteral nutrition should be recommended. This approach may reduce systemic disorders and aid in the prevention and rapid resolution of intestinal toxicity.
chemotherapy / gastrointestinal toxicity / case report / TGF-β2-enriched enteral nutrition
| [1] |
Malignant neoplasms in Russia in 2019 (incidence and mortality). Ed. by Kaprin AD, Starinsky VV, Shakhzadova AO. Moscow: P.A. Herzen Moscow Oncology Research Institute; 2020. 252 p. (In Russ.) |
| [2] |
Rumpold H, Niedersüß-Beke D, Heiler C, et al. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer. 2020;20(1):1149. EDN: CLUGMK doi: 10.1186/s12885-020-07656-w |
| [3] |
Cinausero M, Aprile G, Ermacora P, et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front Pharmacol. 2017;8:354. EDN: YFNXML doi: 10.3389/fphar.2017.00354 |
| [4] |
Dahlgren D, Sjöblom M, Hellström PM, Lennernäs H. Chemotherapeutics-induced intestinal mucositis: Pathophysiology and potential treatment strategies. Front Pharmacol. 2021;12:681417. EDN: WGWEEI doi: 10.3389/fphar.2021.681417 |
| [5] |
Brunton LL, Hilal-Dandan R, Knollmann BC. In: Shanahan JF, Lebowitz H (Eds.), Goodman & Gilman’s. The pharmacological basis of therapeutics (13 ed.). McGraw Hill; 2017. |
| [6] |
Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol. 2004;99:1175–1190. doi: 10.1111/j.1572-0241.2004.30192.x |
| [7] |
Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: Diagnosis and management. Clin Gastroenterol Hepatol. 2017;15(2):182–193.e3. doi: 10.1016/j.cgh.2016.07.028 |
| [8] |
Bhatt AP, Pellock SJ, Biernat KA, et al. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proc Nat Acad Sci U S A. 2020;117(13),7374–7381. EDN: CVYIPE doi: 10.1073/pnas.1918095117 |
| [9] |
Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: Gastrointestinal immunomodulation and enteric nervous system toxicity. Am Physiol Gastrointest Liver Physiol. 2015;308(4): G223–G232. doi: 10.1152/ajpgi.00212.2014. |
| [10] |
Qi L, Luo Q, Zhang Y, et al. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32(8):1469–1486. EDN: XATJRX doi: 10.1021/acs.chemrestox.9b00204 |
| [11] |
Ribeiro RA, Wanderley CW, Wong DV, et al. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother Pharmacol. 2016;78(5):881–893. EDN: ZARWMJ doi: 10.1007/s00280-016-3139-y |
| [12] |
Basile D, Di Nardo P, Corvaja C, et al. Mucosal injury during anti-cancer treatment: From pathobiology to bedside. Cancers (Basel). 2019;11(6):857. EDN: PVHNZJ doi: 10.3390/cancers11060857 |
| [13] |
Petruzzelli GJ, Johnson JT, de Vries EJ. Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. Arch Otolaryngol Head Neck Surg. 1990;116(2):209–211. doi: 10.1001/archotol.1990.01870020085023 |
| [14] |
Cetin B, Buyukberber S, Senturk S, et al. Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer. J Thromb Thrombolysis. 2011,31:503–506. EDN: DXDCMR doi: 10.1007/s11239-010-0525-x |
| [15] |
Avi P, Ben Izhar Sh, Orna N, et al. Clostridium difficile infection: associations with chemotherapy, radiation therapy, and targeting therapy treatments. Curr Med Chem. 2016;23(39):4442–4449. doi: 10.2174/0929867323666161028162018 |
| [16] |
Osumi H, Ozaka M, Ishii H, Sasahira N. Severe ischemic colitis after treatment of bile-duct cancer using gemcitabine and cisplatin. Jpn J Clin Oncol. 2015;45(4):402–403. doi: 10.1093/jjco/hyv038 |
| [17] |
Maruya S, Namba A, Matsubara A, et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol. 2006;11(5):403–406. EDN: KMMKWH doi: 10.1007/s10147-006-0587-0 |
| [18] |
Ivanova AS, Obukhova OA. Nutritional support as a part of complex therapy for clostridial infection. Clinical nutrition and metabolism. 2023;4(3):165–175. (In Russ). EDN: AXMVBJ doi: 10.17816/clinutr623270 |
| [19] |
Bannerjee K, Camacho-Hübner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38:270–275. doi: 10.1097/00005176-200403000-00007 |
| [20] |
Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease. Isr Med Assoc J. 2008;10:503–507. |
| [21] |
Bauche D, Marie JC. Transforming growth factor beta: a master regulator of the gut microbiota and immune cell interactions. Clin Transl Immunol. 2017;6:e136. doi: 10.1038/cti.2017.9 |
| [22] |
Fell JME. Control of systemic and local inflammation with transforming growth factor beta containing formulas. J Parenter Enteral Nutr. 2005;29(4):S126–S133. doi: 10.1177/01486071050290S4S126 |
| [23] |
Mikhailova TL, Romanov RI, Kostenko NV, et al. Experience with enteral nutrition in the treatment of patients with Crohn’s disease of the colon and ulcerative colitis. Koloproktologiya. 2006;1(15):19–23. (In Russ.) EDN: MNIZKV |
| [24] |
Ferreira TMR, Albuquerque A, Cancela Penna FG, et al. Effect of oral nutrition supplements and TGF-beta2 on nutrition and inflammatory patterns in patients with active Crohn’s disease. Nutr Clin Pract. 2020;35(5):885–893. doi: 10.1002/ncp.10448 |
| [25] |
Antoun S, Boige V, Ducreux M, et al. Protective effect of an enteral formula containing TGF-b2 in the prevention of chemotherapy-induced diarrhoea: a pilot study. Eur e-J Clin Nutr Metabol. 2009;4:348–350. doi: 10.1016/j.eclnm.2009.10.005 |
| [26] |
Demiral S, Beyzadeoglu M, Sager O, et al. Evaluation of transforming growth factor-beta2 for radiation-induced diarrhea after pelvic radiotherapy. Tumori. 2015;101(5):474–477. doi: 10.5301/tj.5000328 |
| [27] |
Morello E, Brambilla G, Bernardi S, et al. Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation. Transpl Immunol. 2023;81:101954. EDN: UIODXS doi: 10.1016/j.trim.2023.101954 |
Eco-Vector
/
| 〈 |
|
〉 |